New Zealand PHARMAC Proposes Lifting Restrictions On Merck’s Fosamax; Reduces Subsidy For EC Aspirin
This article was originally published in PharmAsia News
Executive Summary
PERTH, Australia - New Zealand's Pharmaceutical Management Agency has proposed lifting some of the restrictions on drugs classified for musculoskeletal system therapies, effective March 1, the agency announced Jan. 12